+

PE20080072A1 - Compuestos heterociclicos como inhibidores de proteasas serinas - Google Patents

Compuestos heterociclicos como inhibidores de proteasas serinas

Info

Publication number
PE20080072A1
PE20080072A1 PE2007000436A PE2007000436A PE20080072A1 PE 20080072 A1 PE20080072 A1 PE 20080072A1 PE 2007000436 A PE2007000436 A PE 2007000436A PE 2007000436 A PE2007000436 A PE 2007000436A PE 20080072 A1 PE20080072 A1 PE 20080072A1
Authority
PE
Peru
Prior art keywords
alkyl
inhibitors
heterocyclic compounds
serine proteases
protease
Prior art date
Application number
PE2007000436A
Other languages
English (en)
Inventor
David Thomas Parker
Mohindra Seepersaud
Branko Radetich
Aregahegn Yifru
Prakash Raman
Jiping Fu
Michael Patane
Rui Zheng
Oliver Simic
Trixi Brandl
Pascal Rigollier
Francois Lenoir
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080072A1 publication Critical patent/PE20080072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE y ES 0 O 1; n Y p SON 0, 1 O 2; R14 ES C(O) O SO2; R1, R2, W, R13 Y V SON ALQUILO, HETEROCICLILO, AMINO, ARILAMINO, ENTRE OTROS; R3 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C6, ENTRE OTROS; R4 ES H, ALQUILO C1-C4, ARILO, ENTRE OTROS; X ES O, S, N, NR5, ENTRE OTROS; R5 ES O, OH, ALQUILO C1-C8, ENTRE OTROS; R6 Y R7 SON OH, AMINO, ALQUILO C1-C4, ENTRE OTROS; R8, R9, R10, R11 Y R12 SON H, ALQUILO C1-C4, CICLOALQUILO C3-C6, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEASA, EN PARTICULAR DE LA PROTEASA NS3 DEL VIRUS DE LA HEPATITIS C
PE2007000436A 2006-04-11 2007-04-10 Compuestos heterociclicos como inhibidores de proteasas serinas PE20080072A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79131806P 2006-04-11 2006-04-11
US86687406P 2006-11-22 2006-11-22

Publications (1)

Publication Number Publication Date
PE20080072A1 true PE20080072A1 (es) 2008-03-28

Family

ID=38617501

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000534A PE20121157A1 (es) 2006-04-11 2007-04-10 Compuestos heterociclicos como inhibidores de proteasas serinas
PE2007000436A PE20080072A1 (es) 2006-04-11 2007-04-10 Compuestos heterociclicos como inhibidores de proteasas serinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000534A PE20121157A1 (es) 2006-04-11 2007-04-10 Compuestos heterociclicos como inhibidores de proteasas serinas

Country Status (27)

Country Link
US (4) US7825152B2 (es)
EP (2) EP2007789B1 (es)
JP (1) JP5167244B2 (es)
KR (1) KR101059593B1 (es)
CN (1) CN101466727B (es)
AR (1) AR060405A1 (es)
AU (1) AU2007249668B2 (es)
BR (1) BRPI0710878A2 (es)
CA (1) CA2643680A1 (es)
CL (1) CL2007001005A1 (es)
CR (1) CR10336A (es)
EC (1) ECSP088811A (es)
ES (1) ES2543840T3 (es)
HK (1) HK1126798A1 (es)
IL (1) IL194434A0 (es)
MA (1) MA30392B1 (es)
MX (1) MX2008013119A (es)
MY (1) MY147247A (es)
NO (1) NO20084749L (es)
NZ (1) NZ571826A (es)
PE (2) PE20121157A1 (es)
RU (1) RU2448976C2 (es)
SG (1) SG173368A1 (es)
TN (1) TNSN08400A1 (es)
TW (1) TWI341207B (es)
UA (1) UA100666C2 (es)
WO (1) WO2007133865A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148407A1 (en) 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
TW200902520A (en) * 2007-05-10 2009-01-16 Intermune Inc Novel peptide inhibitors of hepatitis C virus replication
EA020951B1 (ru) * 2007-10-10 2015-03-31 Новартис Аг Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
JP5627569B2 (ja) 2008-04-30 2014-11-19 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドＳｉｅｍｅｎｓ Ｍｅｄｉｃａｌ Ｓｏｌｕｔｉｏｎｓ ＵＳＡ，Ｉｎｃ． 新規基質に基づくｐｅｔ造影剤
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
JP5909495B2 (ja) * 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
CA2813337A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Salts and polymorphs of sulfamide ns3 inhibitors
WO2013025858A1 (en) * 2011-08-16 2013-02-21 Glaxosmithkline Llc 5-benzyl-n-phenyethyl-1,3,4-oxadiazole-2-carboxamide derivatives
EP2871181B1 (en) * 2013-11-12 2016-10-05 Acousia Therapeutics GmbH Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues
CN105769860A (zh) * 2016-04-18 2016-07-20 乔海灵 氯美噻唑作为预防和治疗肝脏及食管疾病药物的应用
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN114685453A (zh) 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
US20190167619A1 (en) * 2016-08-08 2019-06-06 Signum Biosciences, Inc. Pharmaceutical formulations and their use
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
DE3803225A1 (de) * 1988-02-04 1989-08-17 Hoechst Ag Aminosaeureamide mit psychotroper wirkung, verfahren zu ihrer herstellung, sie enthaltende mittel und deren verwendung
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
PL169273B1 (pl) 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
EP0527815B1 (en) 1990-04-06 2000-07-19 Genelabs Technologies, Inc. Hepatitis c virus epitopes
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
WO1994014436A1 (en) 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
WO1994019012A2 (en) 1993-02-24 1994-09-01 Wang Jui H Compositions and methods of application of reactive antiviral polymers
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
DE4415539C2 (de) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU2064297A (en) 1996-02-29 1997-09-16 Immusol, Inc Hepatitis c virus ribozymes
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
BR9708735A (pt) 1996-04-23 1999-08-03 Vertex Pharma Derivados de uréia como inibidores da enzina impdh
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CN1133649C (zh) 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
PT1002792E (pt) 1997-04-04 2004-12-31 Mitsubishi Pharma Corp Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
DK1009732T3 (da) 1997-06-30 2003-09-22 Merz Pharma Gmbh & Co Kgaa 1-Amino-alkylcyclohexan NMDA receptor antagonister
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
EP2390257A1 (en) 1998-02-25 2011-11-30 Emory University 2'-fluoronucleosides
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP4294870B2 (ja) 1998-08-10 2009-07-15 インデニックス ファーマシューティカルズ リミティド Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
WO2000059486A2 (en) 1999-04-07 2000-10-12 Pfizer Products Inc. Use of cyp2d6 inhibitors in combination therapies
JP2003517529A (ja) 1999-09-06 2003-05-27 インノヴァシオーネン ツール フェルブレナングステヒニック ゲーエムベーハー 車両用内燃機関及び車両用内燃機関の作動方法
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
AU2001235278A1 (en) 2000-02-18 2001-08-27 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
CN100457118C (zh) 2000-04-13 2009-02-04 法玛塞特有限公司 用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2415678A1 (en) 2000-07-13 2003-01-10 Sankyo Company Limited Amino alcohol derivatives
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
EP1303487A4 (en) 2000-07-21 2005-11-23 Schering Corp NOVEL PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
AU2001255070A1 (en) 2000-08-28 2002-03-13 Jin-Sub Kim Generator of two-wheeled vehicle and lighting system thereby
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
CN101862345B (zh) 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
CA2430458A1 (en) 2000-12-12 2002-06-20 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
BR0116221A (pt) 2000-12-15 2005-09-13 Pharmasset Ltd Agentes antivirais para tratamento de infecções por flaviviridae
ES2278009T3 (es) 2001-01-22 2007-08-01 MERCK & CO., INC. Derivados de nucleosidos como inhibidores de la arn polimerasa virica dependiente de arn.
DE10102928B4 (de) 2001-01-23 2004-03-04 Infineon Technologies Ag Viterbi-Decoder und Verfahren zur Decodierung
BR0208365A (pt) 2001-03-26 2004-03-09 Novartis Ag Derivados de 2-amino-propanol
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ES2292809T3 (es) 2001-09-27 2008-03-16 Kyorin Pharmaceutical Co., Ltd. Derivado de sulfuro de diarilo, sal de adicion del mismo, y agente inmunosupresor.
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
MXPA04004966A (es) 2001-11-27 2006-03-21 Anadys Pharmaceuticals Inc Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
US6973322B2 (en) 2001-12-22 2005-12-06 International Business Machines Corporation Personal travel agent using push services
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
IL162828A0 (en) * 2002-01-23 2005-11-20 Schering Corp Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
EP1497282A2 (en) * 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1536804A4 (en) 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004108687A2 (en) 2003-06-04 2004-12-16 Genelabs Technologies, Inc. Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
ES2354817T3 (es) 2003-06-17 2011-03-18 Schering Corporation Procedimiento y productos intermedios para la preparación de 3-azabiciclo[3.1.0]hexano-2-carboxilatos de (1r,2s,5s)-6,6-dimetilo o sus sales.
PE20050251A1 (es) * 2003-07-18 2005-04-13 Vertex Pharma Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc
RU2355687C2 (ru) 2003-08-01 2009-05-20 Дженелэбс Текнолоджиз, Инк Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
ATE465742T1 (de) 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
JP4685775B2 (ja) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RU2006118359A (ru) 2003-10-27 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Комбинации для лечения вирусного гепатита с (hcv)
KR20060118532A (ko) 2003-12-11 2006-11-23 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제
JP2008505849A (ja) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
DK1730110T3 (da) 2004-02-27 2010-09-27 Schering Corp Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease
AU2005219859A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
AR048413A1 (es) * 2004-02-27 2006-04-26 Schering Corp Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c
CA2557247A1 (en) * 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005085242A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
CN1964985A (zh) 2004-06-07 2007-05-16 阿纳迪斯药物公司 3－β－D－呋喃核糖基噻唑并[4,5－d]嘧啶核苷类及其应用
MXPA06014253A (es) 2004-06-08 2007-07-13 Vertex Pharma Composiciones farmaceuticas.
KR20070043831A (ko) * 2004-07-12 2007-04-25 아이디유엔 파마슈티칼즈, 인코포레이티드 테트라펩티드 유사체
MX2007002371A (es) * 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
US20080267915A1 (en) 2004-10-01 2008-10-30 Vertex Pharmaceuticals Hcv Ns3-Ns4a Protease Inhibition
ES2357587T3 (es) 2004-10-01 2011-04-27 Debiopharm S.A. Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c.
CA2583494C (en) 2004-10-01 2014-01-21 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
ZA200705872B (en) 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130626A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
EP2402331A1 (en) 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
BRPI0710153A2 (pt) 2006-04-11 2011-08-02 Novartis Ag compostos orgánicos e seus usos
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
BRPI0710183A2 (pt) 2006-04-11 2011-08-09 Novartis Ag compostos orgánicos e seus usos
MX2008013119A (es) * 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
EA020951B1 (ru) * 2007-10-10 2015-03-31 Новартис Аг Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors

Also Published As

Publication number Publication date
MY147247A (en) 2012-11-14
MA30392B1 (fr) 2009-05-04
EP2518079A2 (en) 2012-10-31
WO2007133865A3 (en) 2008-07-10
SG173368A1 (en) 2011-08-29
EP2518079A3 (en) 2012-12-12
KR101059593B1 (ko) 2011-08-25
CN101466727B (zh) 2012-10-17
WO2007133865A2 (en) 2007-11-22
US20100331243A1 (en) 2010-12-30
ES2543840T3 (es) 2015-08-24
TNSN08400A1 (en) 2010-04-14
US20130149281A1 (en) 2013-06-13
AR060405A1 (es) 2008-06-11
BRPI0710878A2 (pt) 2015-03-31
RU2008144299A (ru) 2010-05-20
CL2007001005A1 (es) 2008-07-11
US7825152B2 (en) 2010-11-02
CN101466727A (zh) 2009-06-24
KR20080111123A (ko) 2008-12-22
NO20084749L (no) 2008-11-10
US20120231998A1 (en) 2012-09-13
TWI341207B (en) 2011-05-01
JP2009533464A (ja) 2009-09-17
RU2448976C2 (ru) 2012-04-27
US20070286842A1 (en) 2007-12-13
UA100666C2 (uk) 2013-01-25
TW200815478A (en) 2008-04-01
CR10336A (es) 2008-12-03
JP5167244B2 (ja) 2013-03-21
HK1126798A1 (en) 2009-09-11
PE20121157A1 (es) 2012-09-14
AU2007249668B2 (en) 2011-04-07
CA2643680A1 (en) 2007-11-22
IL194434A0 (en) 2011-08-01
ECSP088811A (es) 2008-11-27
AU2007249668A1 (en) 2007-11-22
EP2007789A2 (en) 2008-12-31
NZ571826A (en) 2012-01-12
EP2007789B1 (en) 2015-05-20
US8445527B2 (en) 2013-05-21
MX2008013119A (es) 2008-10-21
US8211932B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20091237A1 (es) Derivados de pirrolidina como moduladores de serina proteasas
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
PE20050940A1 (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
PE20051150A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
PE20070073A1 (es) Compuestos heterociclicos como inhibidores de proteasas
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20120517A1 (es) Inhibidores del virus de la hepatitis c
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
NO20056047L (no) Hepatitt C inhibitor forbindelser
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20140015A1 (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
JO2593B1 (en) Protease inhibitors NS3 hepatitis C HCV virus
ATE478889T1 (de) Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease
EA200800670A1 (ru) Ингибиторы сериновых протеаз
PE20081792A1 (es) Inhibidores de serina proteasas
HK1095820A1 (en) 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
DE602005023015D1 (de) Indolderivate als viruzide
PE20080429A1 (es) Analogos de piperidina, morfolina y pirrolidinilo
EP2504344A4 (en) HEPATITIS C INHIBITOR COMPOUNDS

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载